G Cavalli, CA Dinarello - Frontiers in pharmacology, 2018 - frontiersin.org
Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL- 1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory …
CA Dinarello, A Simon… - Nature reviews Drug …, 2012 - nature.com
Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …
The inflammasome is a molecular platform formed by activation of an innate immune pattern recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC …
CA Dinarello, JWM van der Meer - Seminars in immunology, 2013 - Elsevier
IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …
Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human …
CA Dinarello - European journal of immunology, 2011 - Wiley Online Library
An expanding spectrum of acute and chronic non‐infectious inflammatory diseases is uniquely responsive to IL‐1β neutralization. IL‐1β‐mediated diseases are often called “auto …
NM Ter Haar, M Oswald, J Jeyaratnam… - Annals of the …, 2015 - ard.bmj.com
Autoinflammatory diseases are characterised by fever and systemic inflammation, with potentially serious complications. Owing to the rarity of these diseases, evidence-based …
N Ter Haar, H Lachmann, S Özen, P Woo… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the response to treatment of autoinflammatory diseases from an international registry and an up-to-date literature review. Methods The response to treatment …